Skip to Content
Search Menu

WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

With more than 5 years of follow-up in the Keynote-010 study, pembrolizumab continued to provide clinically meaningful improvement in OS and PFS versus docetaxel in patients with previously treated, PD-L1–positive advanced NSCLC.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
ESMO22Lung cancerNSCLC Play the Video 5:14
Roy S. Herbst

New combination with durvalumab improved ORR and PFS for unresectable Stage III NSCLC

/ Roy S. Herbst
ESMO21NSCLC Play the Video 4:03
Nir Peled

Osimertinib induction for patients with stage III metastatic EGFR NSCLC led to tumor shrinkage

/ Nir Peled
ESMO21NSCLC Play the Video 8:10
Back to top